PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech’s joint venture, Cortexa, has started manufacturing GMP LaNeo™ MDMA capsules in Australia, marking a key advancement in the nation’s psychedelic therapy sector. This move eradicates the need for imports, ensuring a stable local supply for clinical trials and authorized prescribers. The partnership with Perth-based Optima Ovest as the contract manufacturer bolsters domestic production capabilities, signaling PharmAla’s commitment to the Australian market and patient accessibility.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
